CommercialCoverageMedium impact
08.01.15h, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
The policy for Golimumab (Simponi Aria®) IV injection has been updated for commercial plans. This affects billing and coverage criteria for this specialty rheumatology medication used to treat autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease.
Action Required
Before October 1, 2025: Billing team should review the updated policy at the provided URL to understand new coverage criteria and prior authorization requirements for Golimumab (Simponi Aria®) IV injections. Update billing protocols and inform providers of any changes to medical necessity documentation requirements for commercial plans.